Genetic and phenotypic spectrum associated with IFIH1 gain-of-function.
Alleles
Autoimmune Diseases of the Nervous System
/ diagnosis
DNA Mutational Analysis
Female
Gain of Function Mutation
Genetic Association Studies
/ methods
Genotype
High-Throughput Nucleotide Sequencing
Humans
Interferon-Induced Helicase, IFIH1
/ chemistry
Male
Models, Molecular
Nervous System Malformations
/ diagnosis
Phenotype
Protein Conformation
Structure-Activity Relationship
Aicardi-Goutières syndrome
IFIH1
MDA5
Singleton Merten syndrome
Type I interferonopathy
Journal
Human mutation
ISSN: 1098-1004
Titre abrégé: Hum Mutat
Pays: United States
ID NLM: 9215429
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
15
10
2019
revised:
11
12
2019
accepted:
30
12
2019
pubmed:
4
1
2020
medline:
23
7
2021
entrez:
4
1
2020
Statut:
ppublish
Résumé
IFIH1 gain-of-function has been reported as a cause of a type I interferonopathy encompassing a spectrum of autoinflammatory phenotypes including Aicardi-Goutières syndrome and Singleton Merten syndrome. Ascertaining patients through a European and North American collaboration, we set out to describe the molecular, clinical and interferon status of a cohort of individuals with pathogenic heterozygous mutations in IFIH1. We identified 74 individuals from 51 families segregating a total of 27 likely pathogenic mutations in IFIH1. Ten adult individuals, 13.5% of all mutation carriers, were clinically asymptomatic (with seven of these aged over 50 years). All mutations were associated with enhanced type I interferon signaling, including six variants (22%) which were predicted as benign according to multiple in silico pathogenicity programs. The identified mutations cluster close to the ATP binding region of the protein. These data confirm variable expression and nonpenetrance as important characteristics of the IFIH1 genotype, a consistent association with enhanced type I interferon signaling, and a common mutational mechanism involving increased RNA binding affinity or decreased efficiency of ATP hydrolysis and filament disassembly rate.
Identifiants
pubmed: 31898846
doi: 10.1002/humu.23975
pmc: PMC7457149
mid: NIHMS1618607
doi:
Substances chimiques
IFIH1 protein, human
EC 3.6.1.-
Interferon-Induced Helicase, IFIH1
EC 3.6.4.13
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
837-849Subventions
Organisme : Department of Health
ID : TRF-2016-09-002
Pays : United Kingdom
Organisme : National Center for Advancing Translational Sciences of the National Institutes of Health
ID : KL2TR001879
Pays : International
Organisme : NCATS NIH HHS
ID : KL2 TR001879
Pays : United States
Organisme : NICHD NIH HHS
ID : U01 HD082806
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS106845
Pays : United States
Informations de copyright
© 2020 The Authors. Human Mutation published by Wiley Periodicals, Inc.
Références
Br J Dermatol. 2015 Dec;173(6):1505-13
pubmed: 26284909
Medicine (Baltimore). 2018 Dec;97(52):e13893
pubmed: 30593198
Mol Genet Metab. 2018 Dec;125(4):351-358
pubmed: 30219631
Hum Mutat. 2018 Aug;39(8):1076-1080
pubmed: 29782060
Arthritis Rheumatol. 2017 Oct;69(10):2081-2091
pubmed: 28605144
Neurology. 2015 Jul 28;85(4):381-3
pubmed: 26136517
Eur J Hum Genet. 2017 Dec;25(12):1364-1376
pubmed: 29158550
Nat Rev Immunol. 2015 Jul;15(7):429-40
pubmed: 26052098
Lancet Neurol. 2013 Dec;12(12):1159-69
pubmed: 24183309
Nat Genet. 2014 May;46(5):503-509
pubmed: 24686847
Neurology. 2018 Feb 6;90(6):289-291
pubmed: 29321238
J Clin Immunol. 2018 Nov;38(8):844-846
pubmed: 30443754
Am J Hum Genet. 2014 Jul 3;95(1):121-5
pubmed: 24995871
Am J Med Genet A. 2017 May;173(5):1396-1399
pubmed: 28319323
Am J Hum Genet. 2015 Feb 5;96(2):275-82
pubmed: 25620204
Curr Opin Virol. 2015 Jun;12:20-5
pubmed: 25676875
J Interferon Cytokine Res. 2017 May;37(5):214-219
pubmed: 28475458
Cell. 2018 Feb 8;172(4):797-810.e13
pubmed: 29395326